Market Overview

Hemispherx Biopharma Says FDA Panel Voted 9-4 Against Ampligen Effocacy

Share:
Related HEB
Hemispherx Biopharma Enters Into Direct Supply Agreement With Gulf Coast Regional Blood Center to Supply Leukocytes to Manufacture Alferon N Injection(R)
Hemispherx Biopharma Extends Its Strategic Alliance With Armada Health Care for Alferon N Injection
Premarket Biotech Digest: Shorts Targeting Biotech, Anavex's Promise, Zarxio Launch (Seeking Alpha)

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee (the "AAC") of the U.S. Food and Drug Administration (the "FDA") on the New Drug Application ("NDA") for Ampligen^® for Chronic Fatigue Syndrome ("CFS").

On the question: "Considering the totality of the data, is there substantial evidence of efficacy for Ampligen for the treatment of patients with chronic fatigue syndrome (CFS)?," the AAC voted 9 no, 4 yes and 1 AAC member left the room and did not vote.

Posted-In: News FDA

 

Related Articles (HEB)

View Comments and Join the Discussion!

Get Benzinga's Newsletters